This is a thrilling time for the use of measurable residual disease (MRD) in acute myeloid leukemia (AML), as highlighted here by Christopher Hourigan, MD, DPhil, of the National Heart, Lung, and Blood Institute, NIH, Bethesda, MD. Dr Hourigan explains the developments in this field, including updated response criteria and the recent publication of a consensus criteria on the measurement of MRD in AML. This video was recorded at the at the 23rd congress of the European Haematology Association (EHA) 2018, held in Stockholm, Sweden.
Developments for the use of MRD in AML
